TMS Co., Ltd【JP:4891】Other
Market cap
¥6.2B
P/E ratio
Timbs Inc. develops anti-inflammatory drugs from black mold compounds, targeting diseases like stroke and inflammatory conditions through partnerships with major pharmaceutical companies.
| 2018/02 | 2019/02 | 2020/02 | 2021/02 | 2022/02 | 2023/02 | 2024/02 | 2025/02 | 2025/12 | |
| Return on Assets | - | - | - | - | 92.6 | -3.3 | -10.8 | -20.1 | -1 |
| Return on equity (%) | - | - | - | ||||||
| Employees | 4 | 3 | 5 | 6 | 8 | 14 | 14 | 18 | - |